Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and ...

Rigel Pharmaceuticals (RIGL) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #2 (Buy). An upward trend in earnings estimates -- one of the most powerful forces ...

Rigel Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. It discovers and develops novel, targeted drugs in the therapeutic areas of immunology, oncology and immune oncology.

Viewers follow a twisted fairytale, watching as Rigel breaks free from a toxic upbringing by overcoming emotional torture and ...

SOUTH SAN FRANCISCO, Calif., Jan. 13, 2025 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer ...

Rigel Pharmaceuticals (RIGL) announced that the U.S. Food and Drug Administration, FDA, has granted Fast Track designation to R289 for the treatment of patients with previously-treated transfusion ...

Rigel Pharmaceuticals has shown significant growth, particularly from the acquisition of pralsetinib, leading to a 46% improvement in stock valuation since April. Rigel's pipeline includes three ...